Skip to main content

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

About Catherine Owen Adams

Catherine Owen Adams is recorded as Board Member at Agios Pharmaceuticals, Inc. (AGIO) and CEO and Board Member at Acadia Pharmaceuticals Inc (ACAD). Acadia Pharmaceuticals Inc reported in an 8-K filed September 23, 2024 that Catherine Owen Adams was appointed Class III director, effective September 23, 2024. Acadia Pharmaceuticals Inc reported in an 8-K filed September 23, 2024 that Catherine Owen Adams was appointed Chief Executive Officer, effective September 23, 2024. Catherine Owen Adams has spoken on 7 earnings calls across 1 company, most recently for Acadia Pharmaceuticals Inc on August 4, 2026.

“In addition, effective as of the Transition Date, Ms. Owen Adams has been appointed to the Board as a Class III director to serve until the Company’s 2025 annual meeting of stockholders.”
Acadia Pharmaceuticals Inc Form 8-K, filed September 23, 2024 · Read the filing
“On September 20, 2024, the Board appointed Catherine Owen Adams, age 54, to serve as the Chief Executive Officer of the Company, including as the “principal executive officer” of the Company within the meaning of Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended, effective as of the Transition Date.”
Acadia Pharmaceuticals Inc Form 8-K, filed September 23, 2024 · Read the filing

Summary generated from SEC filings and earnings-call records held by Equibles.

Affiliation history

Recorded current and former roles; source labels appear when available.

Company network

Recorded roles and call appearances connecting this person to public companies.

Leadership on record at Acadia Pharmaceuticals Inc

Other people whose current roles at this company are on record from its filings.

Leadership on record at Agios Pharmaceuticals, Inc.

Other people whose current roles at this company are on record from its filings.

Recent activity

Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.